NewAmsterdam Pharma Co N.V. (NAMS) — Cash & Equivalents
| Fiscal Year | Cash & Equivalents | Change YoY |
|---|---|---|
| 2025 | $490.00M | -36.5% |
| 2024 | $771.74M | +126.7% |
| 2023 | $340.45M | — |
| Fiscal Year | Cash & Equivalents | Change YoY |
|---|---|---|
| 2025 | $490.00M | -36.5% |
| 2024 | $771.74M | +126.7% |
| 2023 | $340.45M | — |